Q BioMed Inc.Long
$QBIO back on high alert; shows +68pct Upside Potential!
=====================
QBIO (Q BioMed Inc.)
Alert Price: $2.00
Float: 9.2M
Chart Analysis
Investor Presentation
Fact Sheet
Shareholder Update
Corporate Update Video
========================
Members,
It was an ugly day on Wall St. to say the least.
The Dow Jones Industrial Average dropped 220.77 points to 25,169.53 as Apple and DowDuPont led the decline. The S&P 500 pulled back 0.94 percent to close at 2,706.05, led lower by the energy and tech sectors. The Nasdaq Composite lagged, sliding about 1.2 percent to 7,288.35.
With the global economy in question, we believe that the smart money will once again be flowing back into the microcaps.
This is great news for our members, as we are always on the hunt for the next breakout microcap company.
We wanted to end this week on a high note, and what better way to do that than going with a microcap company that has already delivered some nice returns for our members in the past.
That being said, we ask that you once again turn your immediate attention to QBIO (Q BioMed Inc.).
We first brought this biomedical acceleration and development company to your attention on January 22nd.
Those who acted on that buy call were rewarded to the tune of over +37% in multi-day gains as shares rose from our $1.77 alert price to a high of $2.43.
We've been keeping a close eye on QBIO since then, and are now once again issuing a buy call to our members.
QBIO appears to be oversold at the moment, and we believe that now could be the perfect time to start building a position.
First off, the Company has been getting a lot of press as of late.
Chairman and CEO, Denis Corin recently held an interview with FinancialBuzz from the floor of the NASDAQ MarketSite at Times Square New York City.
During the interview, Mr. Corin shared his vision of the Company's growth and why he believes 2019 and beyond are essential years for QBIO. The interview provides unique insight into the Company's latest corporate developments, updates on recently-achieved milestones, and current upcoming catalyst. Additionally, Mr. Corin provides his perspective on how Q BioMed Inc. is well positioned to build upon its current pipelines and creating continued shareholder value.
FinancialBuzz.com is a respected source in the financial news media space located on Wall Street, and the interview is a much watch for anyone interested in QBIO.
QBIO also announced that CEO Denis Corin will deliver a corporate presentation and conduct one-on-one meetings with investors and potential business partners at the BIO CEO & Investor Conference on February 11th -12th, 2019 in New York City. The BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies.
This is exactly what we meant when we stated in our previous email that the QBIO's management team was committed to its success and growth.
With all these steps in the right direction, we were surprised by the recent pull back for QBIO.
The company has several bullish catalysts working in its favor that we believe will help make it a significant winner once again for our members:
The biotech sector as a whole has been on fire, with the IBB ETF up nearly +20% since December 24th.
QBIO's strong corporate leadership led by CEO Denis Coran.
We've done our very own chart analysis on QBIO, and see as much as +68% in immediate upside potential!
Strong buzz on Twitter
A growing pipeline and strategy that mitigates risk & drives shareholder value.
Acquired the metastatic skeletal cancer palliation drug, Metastron™, from GE Healthcare.The agreement gives QBIO ownership of the brand, trademarks and market authorizations in 22 countries. In addition, all historical and current sales and distribution data related to those market authorisations will be assigned or transferred to QBIO to allow for as seamless a transition as possible in all markets.
QBIO anticipates Metastron™ to start generating revenue in 1H 2019, with gross palliation revenue expected to be 20M-
40M p/a in year 3.
QBIO's QBM-001 treatment for pediatric non-verbal disorder has 55B in global market potential.
QBIO believes that it will complete formulation and manufacturing of QBM-001 by the end of the second quarter of 2019, after which it will file an investigational new drug (IND) application with the FDA. The company is hopeful that QBM-001 may receive the relevant designations from the FDA that could accelerate the development timeline. Assuming authorization from the FDA for the IND, the company believes it could begin a pivotal clinical trial of QBM-001 in the third quarter of 2019, which could lead to reviewed interim data as early as the first quarter of 2020.
Technology partner, Mannin Research, has initiated a collaboration with McMaster University of Ontario, Canada. The collaboration is focused on ophthalmic drug delivery and formulation experiments for MAN-01, a first-in-class small molecule to treat Primary Open-Angle Glaucoma. Experiments will be conducted Dr. Heather Sheardown, a world renowned thought leader in ophthalmic biomaterials and drug delivery.
Now what has us really excited about QBIO, is what we heard during CEO Denis Coran's audio interview with SmallCapVoice.com on January 15th.
At around the twelve minute mark, Mr. Coran hints at an upcoming FDA approval for QBIO's south Texas manufacturing facility.
Once approved QBIO can start producing Metastron™ commercially for sale in the U.S. and then internationally!
This drug is a substantial opportunity for QBIO. A very similar drug with a very narrow indication currently does almost $800 million a year in revenue!
This would be huge news, and could have a major impact on QBIO's stock price.
This is a great and informative interview, and it should get you excited about the incredible opportunity that QBIO presents you at the moment.
We would also like to mention, that just like several of our past big winners, QBIO trades on the OTCQB Venture Marketplace.
Securities trading on OTCQB have higher reporting and certification standards, which tends to lead to increased liquidity, investor confidence, as well as enhanced shareholder value.
If you missed out on QBIO's previous +37% run, you may want to consider jumping on board this time around.
As such, we are urging all members to read our full profile, start their research now, and consider grabbing up a position in QBIO tomorrow morning at 9:30AM EST!
About Q BioMed
Q BioMed, Inc. is a biomedical acceleration and development company. They are focused on licensing and acquiring biomedical assets across the healthcare spectrum. Q BioMed is dedicated to providing these target assets the strategic resources, developmental support and expansion capital they need to meet their developmental potential so that they can provide products to patients in need.
QBIO aims to accelerate the monetization of biomedical technologies through rapid innovation and collaborative partnerships with industry leading researchers. Q BioMed believes its assets in oncology, vascular disease, and rare orphan diseases address unmet medical needs and large markets. The Company's FDA approved, non-opioid drug Metastron, which relieves cancer bone pain, is expected to begin generating revenues in 2019. Metastron is also approved for sale in 21 other countries. In addition to treating pain, Metastron has shown evidence of treating the cancer itself and extending survival. Q BioMed plans to conduct Phase IV trials to support label extension and cancer survival benefit using Metastron.
QBIO approaches biopharmaceutical development from a nontraditional angle. Rather than strictly devoting its resources to internal development, the company licenses what it deems to be undervalued biomedical assets in order to accelerate the achievement of clinical and commercial milestones. The company has five assets in its pipeline, led by its cancer palliation program, and diversified across multiple areas of significant medical need, including developmental nonverbal disorder, liver cancer and glaucoma.
Q BioMed Unlocks Undiscovered Biomedical Value
Targets assets entering validation, clinical stages or commercialization leading up to value creating inflection points
Deploys performance-based capital and resources to accelerate the development of an asset milestone achievement by its management
Licenses or acquires the assets and works together to create valuation growth
How Q BioMed Accelerates Biomedical Technology Development
Unlocks capital in US public markets to fund the development of assets
Makes liquid investments in high-value assets that can produce exponential returns
Diversifies risk over several therapies in various stages of development and deploys performance-based capital only
Accelerates its asset’s development with management and advisory teams' expertise, experience, and industry relationships
Recent Developments
Q BioMed Seeks Multi-billion Dollar Opportunity with New Glaucoma Treatment Candidate
On January 25th, the Company announced that its technology partner, Mannin Research, has initiated a collaboration with McMaster University of Ontario, Canada. The collaboration is focused on ophthalmic drug delivery and formulation experiments for MAN-01, a first-in-class small molecule to treat Primary Open-Angle Glaucoma. Experiments will be conducted Dr. Heather Sheardown, a world renowned thought leader in ophthalmic biomaterials and drug delivery.
CEO of Mannin Research, Dr. George Nikopoulos stated, "This collaboration is extremely important for us and Q BioMed, as well as the MAN-01 program. The Sheardown lab at McMaster University specializes in ophthalmic delivery systems. As we approach our Phase I clinical trial, having the renowned expertise and experience of Dr. Sheardown and her team working with us on delivering our small molecule candidates to the eye is important to our success."
The main objective of the collaboration is to explore novel and better ways of delivering Mannin's small molecules to the eye to treat glaucoma. Using the formulation and drug delivery expertise of the Sheardown laboratory, the collaboration partners are focusing on increasing the compounds' ability to lower intra-ocular pressure to more effectively treat glaucoma.
Q BioMed CEO Denis Corin commented, "Through this collaboration, we are also exploring the use of extended and sustained release formulations with the Mannin compounds for the treatment of other vascular related diseases, such as acute kidney injury, influenza, and myocardial ischemia. We expect the ophthalmic drug delivery data from this collaboration will inform our planned Investigational New Drug (IND) application with the U.S. FDA."
About Dr. Sheardown
Dr. Heather Sheardown holds a Tier 1 Canada Research Chair for Ophthalmic Biomaterials and Drug Delivery Systems. She is an expert in drug delivery, contact lens materials, (intraocular lenses) IOLs, polymer chemistry, and bioengineering in the ophthalmic space. Dr. Sheardown is a Professor in Chemical Engineering and the School of Biomedical Engineering at McMaster University and is cross-appointed with the School of Optometry at the University of Waterloo.
Dr. Sheardown has gained an international reputation for her research on ophthalmic biomaterials, including her innovative work on the development of new materials for contact lenses and drug delivery applications. She has published more than 150 papers in top biomaterials journals, numerous book chapters on ocular materials and drug delivery and has several patents and patents pending on various ophthalmic materials. She has worked extensively with major ophthalmic materials companies including Vistakon, CIBA Vision, Coopervision and AMO, and is the Chief Scientific Officer for a spin-out company, 20/20 OptimEyes Technology.
Dr. Sheardown has an active and vibrant research group of more than 10 graduate students and post-doctoral fellows. Projects in her laboratory involve the development of new polymeric materials and delivery systems for all areas of the eye. These projects are currently supported by C20/20, an Ontario Research Fund grant. This grant is enabling the commercial development of academic-derived technologies and supporting partnerships with corporate partners with co-development opportunities.
Market Outlook
The global cancer therapeutics market should reach $172.6 billion by 2022 from $121 billion in 2017 at a compound annual growth rate (CAGR) of 7.4%, from 2017 to 2022.
Bone Metatases from Prostate and Breast Cancer
450,000 new breast and prostate cancer diagnoses each year
1 in 3 people will develop bone metastases from the spread of breast and prostate cancer
Pediatric Non-Verbal Disorder
Among the >60,000 US children who develop Autism Spectrum Disorders (ASD)
every year,
20,000 become nonverbal and will have to rely on assisted living for the rest of
their life.
Liver Cancer
700,000 patients worldwide
Short 1-year survival rate
Estimated 39,230 adults in the US will be diagnosed every year
Glaucoma
60 million patients worldwide
8 million with bilateral blindness
Typically no early warning signs
Therapy only slows progression, no cure
Technical Analysis
QBIO's stock price has been on a downtrend as of late, but we believe that the bottom is in, and that the upside potential far outweighs the downside risk from here.
CEO Denis Coran addressed the stocks decline in his most recent shareholder update, and we feel confident that he and his management team are well on their way towards reversing this downtrend.
QBIO is trading well off its 52-week high, with plenty of room to the upside.
In fact, a run back to its 52-week high of $4.50 would represent a gain of over +125%!
The float on QBIO is also very thin at just 9.2M, so don't be surprised if we see a big move from this ticker tomorrow.
We've done our very own chart analysis on QBIO, and see as much as +68% in immediate upside potential!
If you missed out on QBIO's previous +37% run, you may want to consider jumping on board this time around!
We are urging all members to start their research now, and consider grabbing up a position in QBIO tomorrow morning at 9:30AM EST!
(*Remember to use a Stop-Loss Order or basic Limit Order to protect your gains, as well as limit possible losses.)
Best Regards,
The TopMarketGainers Team
Don't Miss Our Next Huge Winner...
Text 'GAINS' to '67076'
to have our Trade Alerts
Delivered Direct
to your Cell Phone.
(There is no charge.
Msg&data rates may apply.)
DISCLAIMER
This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by both MJ Capital, LLC and PennyStockLocks, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to MJ Capital, LLC and PennyStockLocks, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.
We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. MJ Capital does NOT own any shares of the companies mentioned herewithin, nor intends to buy any in the future.
MJ Capital’s business model is to receive financial compensation to promote public companies. We have been compensated ten thousand dollars by Awareness Consulting Network to conduct investor relations advertising and marketing for QBIO. We have been previosuly compensated ten thousand dollars by Awareness Consulting Network to conduct investor relations advertising and marketing for QBIO. Any compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MJ Capital often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
QBIO (Q BioMed Inc.)
Alert Price: $2.00
Float: 9.2M
Chart Analysis
Investor Presentation
Fact Sheet
Shareholder Update
Corporate Update Video
========================
Members,
It was an ugly day on Wall St. to say the least.
The Dow Jones Industrial Average dropped 220.77 points to 25,169.53 as Apple and DowDuPont led the decline. The S&P 500 pulled back 0.94 percent to close at 2,706.05, led lower by the energy and tech sectors. The Nasdaq Composite lagged, sliding about 1.2 percent to 7,288.35.
With the global economy in question, we believe that the smart money will once again be flowing back into the microcaps.
This is great news for our members, as we are always on the hunt for the next breakout microcap company.
We wanted to end this week on a high note, and what better way to do that than going with a microcap company that has already delivered some nice returns for our members in the past.
That being said, we ask that you once again turn your immediate attention to QBIO (Q BioMed Inc.).
We first brought this biomedical acceleration and development company to your attention on January 22nd.
Those who acted on that buy call were rewarded to the tune of over +37% in multi-day gains as shares rose from our $1.77 alert price to a high of $2.43.
We've been keeping a close eye on QBIO since then, and are now once again issuing a buy call to our members.
QBIO appears to be oversold at the moment, and we believe that now could be the perfect time to start building a position.
First off, the Company has been getting a lot of press as of late.
Chairman and CEO, Denis Corin recently held an interview with FinancialBuzz from the floor of the NASDAQ MarketSite at Times Square New York City.
During the interview, Mr. Corin shared his vision of the Company's growth and why he believes 2019 and beyond are essential years for QBIO. The interview provides unique insight into the Company's latest corporate developments, updates on recently-achieved milestones, and current upcoming catalyst. Additionally, Mr. Corin provides his perspective on how Q BioMed Inc. is well positioned to build upon its current pipelines and creating continued shareholder value.
FinancialBuzz.com is a respected source in the financial news media space located on Wall Street, and the interview is a much watch for anyone interested in QBIO.
QBIO also announced that CEO Denis Corin will deliver a corporate presentation and conduct one-on-one meetings with investors and potential business partners at the BIO CEO & Investor Conference on February 11th -12th, 2019 in New York City. The BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies.
This is exactly what we meant when we stated in our previous email that the QBIO's management team was committed to its success and growth.
With all these steps in the right direction, we were surprised by the recent pull back for QBIO.
The company has several bullish catalysts working in its favor that we believe will help make it a significant winner once again for our members:
The biotech sector as a whole has been on fire, with the IBB ETF up nearly +20% since December 24th.
QBIO's strong corporate leadership led by CEO Denis Coran.
We've done our very own chart analysis on QBIO, and see as much as +68% in immediate upside potential!
Strong buzz on Twitter
A growing pipeline and strategy that mitigates risk & drives shareholder value.
Acquired the metastatic skeletal cancer palliation drug, Metastron™, from GE Healthcare.The agreement gives QBIO ownership of the brand, trademarks and market authorizations in 22 countries. In addition, all historical and current sales and distribution data related to those market authorisations will be assigned or transferred to QBIO to allow for as seamless a transition as possible in all markets.
QBIO anticipates Metastron™ to start generating revenue in 1H 2019, with gross palliation revenue expected to be 20M-
40M p/a in year 3.QBIO's QBM-001 treatment for pediatric non-verbal disorder has 55B in global market potential.
QBIO believes that it will complete formulation and manufacturing of QBM-001 by the end of the second quarter of 2019, after which it will file an investigational new drug (IND) application with the FDA. The company is hopeful that QBM-001 may receive the relevant designations from the FDA that could accelerate the development timeline. Assuming authorization from the FDA for the IND, the company believes it could begin a pivotal clinical trial of QBM-001 in the third quarter of 2019, which could lead to reviewed interim data as early as the first quarter of 2020.
Technology partner, Mannin Research, has initiated a collaboration with McMaster University of Ontario, Canada. The collaboration is focused on ophthalmic drug delivery and formulation experiments for MAN-01, a first-in-class small molecule to treat Primary Open-Angle Glaucoma. Experiments will be conducted Dr. Heather Sheardown, a world renowned thought leader in ophthalmic biomaterials and drug delivery.
Now what has us really excited about QBIO, is what we heard during CEO Denis Coran's audio interview with SmallCapVoice.com on January 15th.
At around the twelve minute mark, Mr. Coran hints at an upcoming FDA approval for QBIO's south Texas manufacturing facility.
Once approved QBIO can start producing Metastron™ commercially for sale in the U.S. and then internationally!
This drug is a substantial opportunity for QBIO. A very similar drug with a very narrow indication currently does almost $800 million a year in revenue!
This would be huge news, and could have a major impact on QBIO's stock price.
This is a great and informative interview, and it should get you excited about the incredible opportunity that QBIO presents you at the moment.
We would also like to mention, that just like several of our past big winners, QBIO trades on the OTCQB Venture Marketplace.
Securities trading on OTCQB have higher reporting and certification standards, which tends to lead to increased liquidity, investor confidence, as well as enhanced shareholder value.
If you missed out on QBIO's previous +37% run, you may want to consider jumping on board this time around.
As such, we are urging all members to read our full profile, start their research now, and consider grabbing up a position in QBIO tomorrow morning at 9:30AM EST!
About Q BioMed
Q BioMed, Inc. is a biomedical acceleration and development company. They are focused on licensing and acquiring biomedical assets across the healthcare spectrum. Q BioMed is dedicated to providing these target assets the strategic resources, developmental support and expansion capital they need to meet their developmental potential so that they can provide products to patients in need.
QBIO aims to accelerate the monetization of biomedical technologies through rapid innovation and collaborative partnerships with industry leading researchers. Q BioMed believes its assets in oncology, vascular disease, and rare orphan diseases address unmet medical needs and large markets. The Company's FDA approved, non-opioid drug Metastron, which relieves cancer bone pain, is expected to begin generating revenues in 2019. Metastron is also approved for sale in 21 other countries. In addition to treating pain, Metastron has shown evidence of treating the cancer itself and extending survival. Q BioMed plans to conduct Phase IV trials to support label extension and cancer survival benefit using Metastron.
QBIO approaches biopharmaceutical development from a nontraditional angle. Rather than strictly devoting its resources to internal development, the company licenses what it deems to be undervalued biomedical assets in order to accelerate the achievement of clinical and commercial milestones. The company has five assets in its pipeline, led by its cancer palliation program, and diversified across multiple areas of significant medical need, including developmental nonverbal disorder, liver cancer and glaucoma.
Q BioMed Unlocks Undiscovered Biomedical Value
Targets assets entering validation, clinical stages or commercialization leading up to value creating inflection points
Deploys performance-based capital and resources to accelerate the development of an asset milestone achievement by its management
Licenses or acquires the assets and works together to create valuation growth
How Q BioMed Accelerates Biomedical Technology Development
Unlocks capital in US public markets to fund the development of assets
Makes liquid investments in high-value assets that can produce exponential returns
Diversifies risk over several therapies in various stages of development and deploys performance-based capital only
Accelerates its asset’s development with management and advisory teams' expertise, experience, and industry relationships
Recent Developments
Q BioMed Seeks Multi-billion Dollar Opportunity with New Glaucoma Treatment Candidate
On January 25th, the Company announced that its technology partner, Mannin Research, has initiated a collaboration with McMaster University of Ontario, Canada. The collaboration is focused on ophthalmic drug delivery and formulation experiments for MAN-01, a first-in-class small molecule to treat Primary Open-Angle Glaucoma. Experiments will be conducted Dr. Heather Sheardown, a world renowned thought leader in ophthalmic biomaterials and drug delivery.
CEO of Mannin Research, Dr. George Nikopoulos stated, "This collaboration is extremely important for us and Q BioMed, as well as the MAN-01 program. The Sheardown lab at McMaster University specializes in ophthalmic delivery systems. As we approach our Phase I clinical trial, having the renowned expertise and experience of Dr. Sheardown and her team working with us on delivering our small molecule candidates to the eye is important to our success."
The main objective of the collaboration is to explore novel and better ways of delivering Mannin's small molecules to the eye to treat glaucoma. Using the formulation and drug delivery expertise of the Sheardown laboratory, the collaboration partners are focusing on increasing the compounds' ability to lower intra-ocular pressure to more effectively treat glaucoma.
Q BioMed CEO Denis Corin commented, "Through this collaboration, we are also exploring the use of extended and sustained release formulations with the Mannin compounds for the treatment of other vascular related diseases, such as acute kidney injury, influenza, and myocardial ischemia. We expect the ophthalmic drug delivery data from this collaboration will inform our planned Investigational New Drug (IND) application with the U.S. FDA."
About Dr. Sheardown
Dr. Heather Sheardown holds a Tier 1 Canada Research Chair for Ophthalmic Biomaterials and Drug Delivery Systems. She is an expert in drug delivery, contact lens materials, (intraocular lenses) IOLs, polymer chemistry, and bioengineering in the ophthalmic space. Dr. Sheardown is a Professor in Chemical Engineering and the School of Biomedical Engineering at McMaster University and is cross-appointed with the School of Optometry at the University of Waterloo.
Dr. Sheardown has gained an international reputation for her research on ophthalmic biomaterials, including her innovative work on the development of new materials for contact lenses and drug delivery applications. She has published more than 150 papers in top biomaterials journals, numerous book chapters on ocular materials and drug delivery and has several patents and patents pending on various ophthalmic materials. She has worked extensively with major ophthalmic materials companies including Vistakon, CIBA Vision, Coopervision and AMO, and is the Chief Scientific Officer for a spin-out company, 20/20 OptimEyes Technology.
Dr. Sheardown has an active and vibrant research group of more than 10 graduate students and post-doctoral fellows. Projects in her laboratory involve the development of new polymeric materials and delivery systems for all areas of the eye. These projects are currently supported by C20/20, an Ontario Research Fund grant. This grant is enabling the commercial development of academic-derived technologies and supporting partnerships with corporate partners with co-development opportunities.
Market Outlook
The global cancer therapeutics market should reach $172.6 billion by 2022 from $121 billion in 2017 at a compound annual growth rate (CAGR) of 7.4%, from 2017 to 2022.
Bone Metatases from Prostate and Breast Cancer
450,000 new breast and prostate cancer diagnoses each year
1 in 3 people will develop bone metastases from the spread of breast and prostate cancer
Pediatric Non-Verbal Disorder
Among the >60,000 US children who develop Autism Spectrum Disorders (ASD)
every year,
20,000 become nonverbal and will have to rely on assisted living for the rest of
their life.
Liver Cancer
700,000 patients worldwide
Short 1-year survival rate
Estimated 39,230 adults in the US will be diagnosed every year
Glaucoma
60 million patients worldwide
8 million with bilateral blindness
Typically no early warning signs
Therapy only slows progression, no cure
Technical Analysis
QBIO's stock price has been on a downtrend as of late, but we believe that the bottom is in, and that the upside potential far outweighs the downside risk from here.
CEO Denis Coran addressed the stocks decline in his most recent shareholder update, and we feel confident that he and his management team are well on their way towards reversing this downtrend.
QBIO is trading well off its 52-week high, with plenty of room to the upside.
In fact, a run back to its 52-week high of $4.50 would represent a gain of over +125%!
The float on QBIO is also very thin at just 9.2M, so don't be surprised if we see a big move from this ticker tomorrow.
We've done our very own chart analysis on QBIO, and see as much as +68% in immediate upside potential!
If you missed out on QBIO's previous +37% run, you may want to consider jumping on board this time around!
We are urging all members to start their research now, and consider grabbing up a position in QBIO tomorrow morning at 9:30AM EST!
(*Remember to use a Stop-Loss Order or basic Limit Order to protect your gains, as well as limit possible losses.)
Best Regards,
The TopMarketGainers Team
Don't Miss Our Next Huge Winner...
Text 'GAINS' to '67076'
to have our Trade Alerts
Delivered Direct
to your Cell Phone.
(There is no charge.
Msg&data rates may apply.)
DISCLAIMER
This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by both MJ Capital, LLC and PennyStockLocks, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to MJ Capital, LLC and PennyStockLocks, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.
We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. MJ Capital does NOT own any shares of the companies mentioned herewithin, nor intends to buy any in the future.
MJ Capital’s business model is to receive financial compensation to promote public companies. We have been compensated ten thousand dollars by Awareness Consulting Network to conduct investor relations advertising and marketing for QBIO. We have been previosuly compensated ten thousand dollars by Awareness Consulting Network to conduct investor relations advertising and marketing for QBIO. Any compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MJ Capital often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.